Futura Medical PLC Futura to host EU Advisory Panel Meeting at ESSM
14 Fevereiro 2019 - 5:01AM
RNS Non-Regulatory
TIDMFUM
Futura Medical PLC
14 February 2019
Futura Medical to hold its First European Advisory Panel Meeting
at the European Society of Sexual Medicine (ESSM)
14 February 2019
Futura Medical plc (AIM: FUM) (the "Company"), a pharmaceutical
company developing a portfolio of innovative products for sexual
health and pain relief, today announces that it will host its first
European Key Opinion Leader (KOL) Advisory Panel meeting ahead of
the 21(st) Congress of the ESSM on 14-16 February 2019, at Cultural
and Congress Centre Cankarjev Dom, Ljubljana, Slovenia. This
meeting follows the successful US KOL Advisory Panel meeting at the
Sexual Medicine Society of North America (SMSNA) in November
2018.
As announced on 28 January 2019, Tim Holland, Director of
Clinical Development at Futura Medical, will be presenting safety
data in female partners on its lead product MED2005, a topical
glyceryl trinitrate ("GTN") gel for the treatment of erectile
dysfunction ("ED") at the ESSM. The poster entitled "Establishing
the safety profile in sexual partners of a new topical glyceryl
trinitrate gel for the treatment of erectile dysfunction" on
Thursday 14 February at 15.30 CET. The presentation will be part of
the "Male sexual dysfunction: medical treatment" poster session
held in Foyer 1, Floor 1.
Professor David Ralph, world leading expert in erectile
dysfunction and male infertility and member of the Futura European
KOL Advisory Panel, spoke with Futura Medical's Executive Director
and Head of R&D, Ken James about the unmet need and innovation
in the treatment of ED. A link to the video can be found here.
David is a Consultant Urologist at University College London and
the Institute of Urology,and Former President of the Andrology
Section of the British Association of Urological Surgeons (BAUS);
the British Society for Sexual Medicine (BSSM) and the ESSM.
James Barder, Chief Executive Officer of Futura Medical said: "I
would like to thank Professor Ralph for his support and involvement
in Futura's first R&D Day, which took place in London on Monday
11 February 2019. The event was well received and provided an
opportunity to hear first-hand from a prominent KOL on the
significant negative effect ED has on the quality of life,
relationships and overall wellbeing of ED sufferers and their
partners. The event also provided an opportunity for the Futura
team to describe the Company's R&D strategy with a focus on its
DermaSys(R) drug delivery technology and lead product MED2005. We
look forward to hosting our second Advisory Panel meeting to
further our discussions on the on-going development and educational
programme for MED2005 with a number of eminent European Key Opinion
Leaders."
ENDS
For further information please contact:
Futura Medical plc
James Barder, Chief Executive
Angela Hildreth, Finance Director and COO
Email: Investor.relations@futuramedical.com
Tel: +44 (0) 1483 685 670
Nominated Adviser and Broker:
N+1 Singer
Aubrey Powell/ Ben Farrow (Corporate Finance)
Mia Gardner / Tom Salvesen (Corporate Broking)
Tel: +44 (0) 20 7496 3000
For media enquiries please contact:
Optimum Strategic Communications
Mary Clark/ Hollie Vile/ Ellie Blackwell
Email: futuramedical@optimumcomms.com
Tel: +44 (0) 203 950 9144
Notes to editors
About Futura Medical plc
Futura Medical plc (AIM: FUM), is a pharmaceutical company
developing a portfolio of innovative products based on its
proprietary, transdermal DermaSys(R) drug delivery technology.
These products are optimised for clinical efficacy, safety,
administration and patient convenience and are developed for the
prescription and consumer healthcare markets as appropriate.
Current therapeutic areas are sexual health, including erectile
dysfunction, and pain relief. Development and commercialisation
strategies are designed to maximise product differentiation and
value creation whilst minimising risk.
Futura is based in Guildford, Surrey, and its shares trade on
the AIM market of the London Stock Exchange.
www.futuramedical.com
About MED2005: Eroxon(R) - Topical treatment for erectile
dysfunction (ED)
MED2005, which uses Futura's DermaSys(R) drug delivery system,
is the development name for its topical glyceryl trinitrate ("GTN")
gel. It has the potential to be a highly differentiated therapy for
the treatment of men with ED, especially mild to moderate ED.
MED2005's rapid onset of action means that it has the potential to
become the world's fastest-acting treatment for ED, with a speed of
onset of around five minutes. Viagra(R) and Cialis(R) which
dominate the existing on-market ED therapies are taken orally and
do not take effect for at least 30 minutes and typically one hour
or more(2) . Speed of onset and method of administration of MED2005
also help restore spontaneity and intimacy. Importantly, MED2005
may also be appropriate for ED sufferers on nitrates and other
drugs that are contraindicated for use with
phosphodiesterase-5-inhibitors ("PDE5Is") such as Viagra(R) and
Cialis(R) and other existing oral ED treatments.
Note 1: Sources, Shabsigh R et al, J Urol 2005; vol. 174,
662-667
EMEA & Withdrawal assessment report for Viagra, 2008
Note 2: US patient information for Viagra(R) and Cialis(R)
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
END
NRADGGDDBDBBGCX
(END) Dow Jones Newswires
February 14, 2019 02:01 ET (07:01 GMT)
Futura Medical (LSE:FUM)
Gráfico Histórico do Ativo
De Abr 2024 até Mai 2024
Futura Medical (LSE:FUM)
Gráfico Histórico do Ativo
De Mai 2023 até Mai 2024